Selpercatinib FoundationOne companion diagnostic - Foundation Medicine/Loxo oncology
Alternative Names: Selpercatinib FoundationOne®CDx - Foundation Medicine/Loxo oncologyLatest Information Update: 18 Sep 2024
Price :
$50 *
At a glance
- Originator Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Solid tumours
Most Recent Events
- 18 Sep 2024 Launched for Solid tumours (Diagnosis) in USA (unspecified route) prior to September 2024 (Foundation Medicine website, September 2024)
- 09 Oct 2023 Registered for Solid tumours (Diagnosis) in USA (unspecified route)
- 15 Feb 2022 Foundation Medicine and Eli Lilly and Company agree to develop selpercatinib FoundationOne companion diagnostic for solid tumours